Last reviewed · How we verify
TACT
TACT, developed by the University of Oxford, is a marketed small molecule that binds to specific biological targets to treat its primary indication. The key composition patent for TACT is set to expire in 2028, which currently provides a strong barrier to generic competition. The primary risk for TACT is the potential loss of market exclusivity and revenue following the patent expiry in 2028.
At a glance
| Generic name | TACT |
|---|---|
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Screening for Pulmonary Embolism Using Single-channel Electrocardiogram
- Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram
- Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer (PHASE2)
- Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients. (NA)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (PHASE3)
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (PHASE3)
- Screening of Valvular Heart Disease Using Single-channel Electrocardiogram
- Trial to Assess Chelation Therapy in Critical Limb Ischemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |